News
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal $1.3 billion, The WSJ reported.
Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...
Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback